Matinas BioPharma Holdings, Inc. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported net loss was USD 5.51 million compared to USD 5.98 million a year ago. Basic loss per share from continuing operations was USD 0.03 compared to USD 0.03 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.1789 USD | -1.43% | -4.69% | -17.25% |
Mar. 27 | Transcript : Matinas BioPharma Holdings, Inc., 2023 Earnings Call, Mar 27, 2024 | |
Mar. 27 | Matinas BioPharma Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-17.25% | 44.87M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- MTNB Stock
- News Matinas BioPharma Holdings, Inc.
- Matinas BioPharma Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023